A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Academic Article uri icon



  • INTRODUCTION: KRAS mutations are present in 30% of lung adenocarcinomas. Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations. METHODS: Two cohorts of patients with stage IIIB/IV lung adenocarcinoma were eligible: patients with tumors with KRAS mutations who were previously treated with chemotherapy and patients receiving initial therapy who had ≥15 pack-year smoking history. Salirasib was given orally from days 1 to 28 of a 35-day cycle. The primary end point was the rate of nonprogression at 10 weeks. RESULTS: Thirty-three patients were enrolled. Thirty patients had KRAS mutations (23 patients who were previously treated and 7/10 patients who had no prior therapy). Of the previously treated patients, 7 of 23 (30%) had stable disease at 10 weeks, and 4 of 10 (40%) previously untreated patients had stable disease at 10 weeks. No patient had a radiographic partial response (0% observed rate, 95% confidence interval 0-12%). The median overall survival was not reached (>9 months) for previously untreated patients and it was 15 months for patients who received prior chemotherapy. Diarrhea, nausea, and fatigue were the most common toxicities. CONCLUSIONS: Salirasib at the current dose and schedule has insufficient activity in the treatment of KRAS mutant lung adenocarcinoma to warrant further evaluation. The successful enrollment of 30 patients with tumors with KRAS mutant lung adenocarcinoma over 15 months at a single site demonstrates that drug trials directed at a KRAS-specific genotype in lung cancer are feasible.

publication date

  • August 1, 2011



  • Adenocarcinoma
  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Farnesol
  • Lung Neoplasms
  • Mutation
  • Proto-Oncogene Proteins
  • Salicylates
  • ras Proteins


Scopus Document Identifier

  • 80051745051

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e318223c099

PubMed ID

  • 21847063

Additional Document Info


  • 6


  • 8